|
Device 15 of 25 e1: complainant street address: calidad cardio perfusion e.I.R.L complainant city: lima complainant state : lurin complainant country: peru based on the available information, this event is deemed to be a reportable malfunction.Photograph, video and/or physical sample evaluation: there were photographs associated with this case and in these, the reported defect can be seen.No unused return sample was expected.Batch record revision results: lot 5f02076 was manufactured on 10/jun/2025, in bodolay line, with a total of (b)(4) market units (mkus).The complaint engineer performed a batch record review on 29/apr/2026, to verify if all the applicable procedures were followed and no issues were found; all the components for assembly were correct per bill of materials (bom) and all the tooling information documented was also correct, system application product (sap) material identification (id) 1704761 and manufacturing order (b)(4).Review of the batch record showed that all relevant tests required during the manufacturing process and final product release had been fulfilled and met the requirements.No discrepancy related to this issue were found within the documentation.Historical complaints review: on 29/apr/2026, complaints engineer ran a query in database in order to verify the complaints reported for the 5f02076 lot for the malfunction ¿foreign matter within product, sterile products (e.G.Metal contamination in dressings, particulates within fluids, gels etc)¿ defect and no additional complaint was identified.Historical nonconformance review: on 29/apr/2026, complaint engineer ran a query in database looking for any in process nonconformance / corrective action / preventive actions (capa) (s) associated to the malfunction ¿foreign matter within product, sterile products (e.G.Metal contamination in dressings, particulates within fluids, gels etc)¿ for the lot number 5f02076 and as result, no nonconformance / capa (s) for this malfunction were generated during the manufacturing process of the referenced lot.Current quality controls: based on the process instruction (pi), the following tests are performed in the manufacturing lines, in order to identify this failure mode in our manufacturing process: test methods (tm)" package seal integrity nonconformities".Method ¿ 7 ¿ frequency: every 30 minutes ¿ sample quantity: 1 market unit o not less than (nlt) 5 chevrons.¿ acceptance criteria: accept = 0 | reject = 1 defect rate analysis: there have been (b)(4) defective parts confirmed to date from a lot size of (b)(4) products.This represents (b)(4).In addition, all the in-process testing on this lot did not find a single defective unit, which confirms that the lot is unlikely to breach an aql of 0.40.Importantly, to date, it is well within our accepted aql level for this type of failure mode or defect.Conclusions: a review of batch records was completed and showed that all relevant tests required during the manufacturing process and final product release had been fulfilled and met the requirements.No discrepancies related to this issue were found within the documentation.This issue will be monitored through the post market product monitoring review process, standard operating procedure (sop).To date no additional information has been received.Should additional information become available, a follow-up report will be submitted.Fda registration number reporting site: 1049092 manufacturing site: 9618003.
|